US-based IACT Health and Canada-based LMC Manna Research have announced an alliance aimed at integrating their operations. Comprising two of the clinical research industry’s largest site networks, the alliance will end up bringing together more than 40 sites, access to more than 1.5m patients, and currently more than 150 active investigations.
According to the companies, the partners will draw upon shared technology, marketing resources, recruitment efforts, business development, and more. The alliance reportedly is aimed at building upon the operational efficiencies that the individual companies already offer their clients.
Jeff Kingsley, CEO of IACT Health, said, “We are thrilled to join forces with such a highly-qualified and reputable research organization that brings such deep experience and a proven track record of delivering on their clinical trials year after year. Both companies share a commitment to quality, safety, patient satisfaction, and customer service that will position us as the preferred option for pharmaceutical and biotech companies, contract research organizations (CROs), patients, and providers alike.”
“LMC Manna Research is excited about the opportunity to work with IACT Health’s talented team, who share our approach to integrated research sites and systems, and place strong emphasis on quality and patient experience,” said Karri Venn, president of LMC Manna Research. “Together, we will offer sponsors and CROs a single point of contact to perform their clinical studies across North America, while providing meaningful and strategic combined research operations across these two networks to create North America’s pre-eminent clinical research network.”
Currently, the largest US network of wholly owned clinical research sites in the southeastern part of the country, IACT Health’s stated mission is advancing research through conducting research with routine healthcare, in addition to urgent and emergency care, while creating outstanding clinical trial experiences, improving outcomes, and lowering the risk and net cost of studies. An assessment conducted by Tufts University determined the company’s proven enrollment is more than 212% of the average research site, and since 2005, IACT Health reportedly has helped more than 80 treatments obtain FDA approval, covering oncology, cardiology, pulmonology, endocrinology, infectious disease, pain, and other areas.
LMC Manna Research (Canada’s largest clinical research network) offers pharmaceutical clients and CROs with a single-source approach to performing clinical trials across a range of treatment areas. The company reportedly seeks to offer fast start-up, high recruitment, and regulatory compliance, with single-source contracting, integrated standard operating procedures, quality assurance, and decentralized trial capabilities.